UNSPSC 51332506: Carperone

This classification denotes an anxiolytic with the molecular formula C19H27FN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q3AP22Z9FJ, chemically known as carbamic acid, isopropyl-, 1-(3-(p-fluorobenzoyl)propyl)piperid-4-yl ester but generally known as carperone, which bears US NIH Compound Identifier 30429. European Medicines Agency schedules Carperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06140MIG.

UNSPSC 51332506 Carperone, a Commodity code, covers pharmaceutical products and related health-supply systems that state and local governments procure for community health, emergency response, and pharmacy benefit programs. Recent solicitations show state and local buyers acquiring naloxone and drug deactivation systems for opioid response, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing agreements, and direct-to-manufacturer prescription fulfillment capabilities. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Work ranges from spot purchases of emergency medications with defined annual volumes to longer-term pharmaceutical supply contracts requiring manufacturer compliance with Good Manufacturing Practices, Drug Supply Chain Security Act certification, and specialized wholesaler relationships. Vendors must meet insurance, E-Verify, and federal regulatory requirements including FDA compliance, Clean Air Act adherence, and potential FEMA funding conditions.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026, to evaluate vendor capability for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The RFP weights price competitiveness at 75 percent and requires cGMP certification, DSCSA compliance, and contractual relationships with at least two of three designated wholesalers.